RYTM analyst estimates
Rhythm Pharmaceuticals (RYTM) analyst ratings, the average price target and its range, and every firm's latest call.
RYTM analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 12, 2026 | H.C. Wainwright | Rhythm Pharmaceuticals (RYTM) PT Raised to $130 at H.C. Wainwright | $130.00 |
| Oct 8, 2026 | RBC Capital | Rhythm Pharmaceuticals price target raised to $159 from $155 at RBC Capital | $159.00 |
| Aug 28, 2026 | Deutsche Bank | Rhythm Pharmaceuticals initiated with a Hold at Deutsche Bank | $120.00 |
| Aug 5, 2026 | National Bank | Rhythm Pharmaceuticals (RYTM) PT Raised to $160 at Citizens on Imcivree Launch | $160.00 |
| Aug 5, 2026 | Canaccord Genuity | Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord | $154.00 |
| Jul 7, 2026 | RBC Capital | Rhythm Pharmaceuticals price target raised to $141 from $137 at RBC Capital | $141.00 |
| Jun 16, 2026 | Canaccord Genuity | Rhythm Pharmaceuticals (RYTM) PT Raised to $151 at Canaccord | $151.00 |
| Jun 15, 2026 | Wells Fargo | Rhythm Pharmaceuticals price target raised to $155 from $144 at Wells Fargo | $155.00 |
| Jun 15, 2026 | Stifel Nicolaus | Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Post Release of Setmelanotide Data | $133.00 |
| May 7, 2026 | Canaccord Genuity | Rhythm Pharmaceuticals price target raised to $143 from $140 at Canaccord | $143.00 |
| Mar 12, 2026 | Wells Fargo | Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo | $143.00 |
| Mar 12, 2026 | Telsey Advisory | Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo | $143.00 |
| Mar 3, 2026 | Jefferies | Jefferies Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM): "We like RYTM into the next 6 months" | $125.00 |
| Feb 26, 2026 | Stifel Nicolaus | Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) | $131.00 |
| Feb 18, 2026 | RBC Capital | RBC Capital Starts Rhythm Pharmaceuticals (RYTM) at Outperform; 'Set' Up to Hit High Notes in Rare Obesity' | $145.00 |
- 14 firms rate RYTM: 13 buy, 1 hold, 0 sell.
- The average price target is $144.43 from 7 analysts, from $120.00 to $160.00.
Updated 2026-11-02 23:10 UTC